alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>
                                                                   EXHIBIT 21.1

PARENT

ANDRX CORPORATION, A DELAWARE CORPORATION, INCORPORATED 3/23/2000

SUBSIDIARIES

Andrx Corporation, a Florida Corporation incorporated 8/28/92*

Andrx Labs, Inc., a Florida Corporation incorporated 2/20/97*

Andrx Laboratories, Inc. - a Mississippi Corporation, incorporated 11/1/95*

Andrx Laboratories (NJ), Inc. - a Delaware Corporation, incorporated 7/13/01*

Andrx Pharmaceuticals, Inc. - a Florida Corporation, incorporated 11/21/94*

Andrx Pharmaceuticals Sales, Inc. - a Florida Corporation, incorporated 9/7/99#

Andrx Pharmaceuticals (NJ), Inc. - a Florida Corporation, incorporated 11/15/99#

Andrx Pharmaceuticals LLC - a Virginia Limited Liability Company
organized 2/11/00#

Andrx Pharmaceuticals Equipment #1 L.C. - a Florida Limited Liability Company,
organized 2/25/99#

Andrx Financial Corp. - a Nevada Corporation, incorporated 11/24/99*

Andrx Foreign Sales Corp. - a BVI corporation, incorporated 9/8/99*

Anina, Inc. - a Florida Corporation, incorporated 5/16/00*

Anina Pharmaceuticals, Inc. - a Florida Corporation, incorporated 5/16/00*

Armstrong Pharmaceuticals, Inc. - a Delaware Corporation, incorporated 2/20/01*

Aspire Pharmaceuticals Equipment #1 LLC - a Florida Limited Liability Company,
organized 11/28/00*

Aura Pharmaceuticals, Inc. - a Florida Corporation, incorporated 9/7/99#

Anda, Inc. - a Florida Corporation, incorporated 9/17/92*

Anda Consumer Products, Inc. - a Florida Corporation, incorporated 6/20/00*

Anda Sales, Inc. - a Florida Corporation, incorporated 9/7/99#

Anda Pharmaceuticals, Inc. - a Florida Corporation, incorporated 6/7/01*

Caran Pharmaceuticals, Inc. - a Nevada Corporation, incorporated 5/8/00#

Cybear, Inc. - a Delaware Corporation, incorporated 2/5/97*

Cybearclub L.C. - a Florida Limited Liability Company, organized 8/25/99#

Mediconsult.com, Inc. - a Delaware Corporation#

Physicians' Online, Inc. - a Delaware Corporation#

SR Six, Inc. - a Florida Corporation, incorporated 7/7/94#

Telegraph Consulting Corp. - a Florida Corporation, incorporated 8/13/99#

Valmed Pharmaceutical, Inc. - a New York Corporation, incorporated 2/11/00*

*Directly owned 100% by Andrx
#Indirectly owned 100% through another Andrx subsidiary
Featured Grant OpportunitySchool Emergency Response to Violence (Project SERV) (Funding Opportunity) 

Featured Grant OpportunityShare with Youth: NOAA Student Opportunities Database

Featured Grant OpportunityShort Courses in Social Determinants of Health for Research Education in Nursing Research (Funding...

Featured Grant OpportunityComprehensive Partnerships to Advance Cancer Health Equity (CPACHE) Program (Funding Opportunity)

Featured Grant OpportunityRisk and Protective Factors of Family Health and Family Level Interventions (Funding Opportunity)

Featured Grant OpportunityPersonnel Development to Improve Services and Results for Children with Disabilities--Doctoral...

Featured Grant OpportunityStanding Announcement for Tribal Title IV-E Plan Development Grants (Funding Opportunity)

Featured Grant OpportunityProviding Research Education Experiences to Enhance Inclusivity for a Diverse Substance Use and...

Featured Grant OpportunityFY 2024 Research on School-Based Hate Crimes (Funding Opportunity)

Featured Grant OpportunityChallenge America (Funding Opportunity)

Featured Grant OpportunityResearch and Evaluation on Firearm Violence and Mass Shootings (Funding Opportunity)

Featured Grant OpportunityNational Juvenile Court Data Archive (Funding Opportunity)

Featured Grant OpportunityGraduate Research Fellowship (Funding Opportunity)

Featured Grant OpportunityCommunity Programs for Outreach and Intervention with Youth and Young Adults at Clinical High Risk...

Featured Grant OpportunityPrint and Disseminate Child Victims and Witnesses Support Materials (Funding Opportunity)

## Breadcrumb

            -  Announcements 
            -           Resource: ABCD Study® Infographics      

# Resource: ABCD Study® Infographics

These infographics showcase research findings of interest to ABCD Study® participants, their families, educators, scientists, and other stakeholders. **Learn more.**
#### § 1210.311 Programs and projects.

*Programs* and *projects* mean those research, development, advertising, or promotion programs or projects developed by the Board pursuant to § 1210.331.
§ 1147.106 Reimbursement claims. ( a ) In order for the eligible dairy organization to receive reimbursement pursuant to § 1147.108, the eligible partnership must submit a Reimbursement Claim Form and appropriate supporting documentation to AMS. ( 1 ) *Required information.* Each Reimbursement Claim Form associated with an approved Dairy Donation and Distribution Plan must include: ( i ) The type and amount of eligible dairy products donated to the eligible distributor;
( ii ) The physical address(es) of the plant(s) or co-pack facility(ies) that processed and, if applicable, distribution center(s) that stored the donated dairy products;
( iii ) The date the eligible dairy products were processed;
( iv ) The date the eligible dairy products were shipped to the eligible distributor;
( v ) The respective sell-by, best-by, or use-by date(s) for the donated dairy products; and
( vi ) Other information as needed on the Reimbursement Claim Form to calculate reimbursement.
( 2 ) *Appropriate verifying documentation.* Each Reimbursement Claim Form must be accompanied by documents verifying that the donation(s) reported in the form were made. Such documentation may include, but is not limited to, copies of processing records, shipping records, bills of lading, warehouse receipts, distribution records, or other documents demonstrating the reported amount of eligible dairy products were processed, donated, and distributed in accordance with the approved Dairy Donation and Distribution Plan and Eligible Distributor Certification Form and as reported on the Reimbursement Claim Form.
( 3 ) *Eligibility period.* To be considered for reimbursement, eligible dairy products must have been donated on or after January 1, 2020, until program funds are expended.
( b ) Incomplete reimbursement requests will be returned to the submitter for revision or completion and resubmission as necessary.
[86 FR 48898, Sept. 1, 2021, as amended at 88 FR 57872, Aug. 24, 2023]
#### 928.101-1 Policy on use.

In addition to the restriction on use of bid guarantees in 48 CFR 28.101-1(a), a bid guarantee may be required only for fixed price or unit price contracts entered into as a result of sealed bidding. They may not be required for negotiated contracts.

[61 FR 41708, Aug. 9, 1996, as amended at 75 FR 29459, May 26, 2010]
#### Dorann P. Johnson et al., Respondents, v Edward L. Ladin, Appellant.

[776 NYS2d 842]

In an action to recover damages for dental malpractice, etc., the defendant appeals from an order of the Supreme Court, Westchester County (Nicolai, J.), dated July 22, 2003, which, in effect, denied his oral application to dismiss the complaint for the plaintiffs’ failure to produce a dental expert for trial.

*675Ordered that the appeal is dismissed, without costs or disbursements, as the order is not appealable as of right and we decline to grant leave to appeal *(see*CPLR 5701). Ritter, J.P., S. Miller, Townes, Crane and Rivera, JJ., concur.
Featured Grant OpportunitySchool Emergency Response to Violence (Project SERV) (Funding Opportunity) 

Featured Grant OpportunityShare with Youth: NOAA Student Opportunities Database

Featured Grant OpportunityShort Courses in Social Determinants of Health for Research Education in Nursing Research (Funding...

Featured Grant OpportunityComprehensive Partnerships to Advance Cancer Health Equity (CPACHE) Program (Funding Opportunity)

Featured Grant OpportunityRisk and Protective Factors of Family Health and Family Level Interventions (Funding Opportunity)

Featured Grant OpportunityPersonnel Development to Improve Services and Results for Children with Disabilities--Doctoral...

Featured Grant OpportunityStanding Announcement for Tribal Title IV-E Plan Development Grants (Funding Opportunity)

Featured Grant OpportunityProviding Research Education Experiences to Enhance Inclusivity for a Diverse Substance Use and...

Featured Grant OpportunityFY 2024 Research on School-Based Hate Crimes (Funding Opportunity)

Featured Grant OpportunityChallenge America (Funding Opportunity)

Featured Grant OpportunityResearch and Evaluation on Firearm Violence and Mass Shootings (Funding Opportunity)

Featured Grant OpportunityNational Juvenile Court Data Archive (Funding Opportunity)

Featured Grant OpportunityGraduate Research Fellowship (Funding Opportunity)

Featured Grant OpportunityCommunity Programs for Outreach and Intervention with Youth and Young Adults at Clinical High Risk...

Featured Grant OpportunityPrint and Disseminate Child Victims and Witnesses Support Materials (Funding Opportunity)

## Breadcrumb

            -           Burning Truth Initiative      

# Burning Truth Initiative

The CDC’s Burning Truth initiative encourages young people to keep their skin healthy by protecting themselves against too much exposure to ultraviolet rays from the sun and tanning beds. 

http://www.cdc.gov/cancer/skin/burningtruth/?utm_source=FindYouthInfo.gov&utm_medium=Federal%20links&utm_campaign=Reports-and-Resources
#### § 1126.54 Equivalent price.

See § 1000.54.
I 

118TH CONGRESS 

1ST SESSION H. R. 1155 

To prohibit the phase out of gasoline and prevent higher prices for consumers, 

and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 24, 2023 

Mr. CRENSHAW (for himself, Mr. WEBER of Texas, Mr. PENCE, Mr. JOYCE

of Pennsylvania, Mr. CARTER of Georgia, and Mr. DUNCAN) introduced 

the following bill; which was referred to the Committee on Energy and 

Commerce 

A BILL 

To prohibit the phase out of gasoline and prevent higher 

prices for consumers, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Keeping America’s Re5 fineries Act’’. 


kjohnson on DSK79L0C42PROD with BILLS
2 

•HR 1155 IH

1 SEC. 2. NO MANDATORY ASSESSMENT OF SAFER TECH2 NOLOGY AND ALTERNATIVE RISK MANAGE3 MENT MEASURES REQUIRED WITH RESPECT 

4 TO THE USE OF HYDROFLUORIC ACID IN 

5 CERTAIN ALKYLATION UNITS. 

6 (a) IN GENERAL.—The owner or operator of a sta7 tionary source described in subsection (b) of this section 

8 shall not be required by the regulations promulgated 

9 under section 112(r)(7)(B) of the Clean Air Act (42 

10 U.S.C. 7412(r)(7)(B)) to include in any hazard assess11 ment under clause (ii) of such section 112(r)(7)(B) an as12 sessment of safer technology and alternative risk manage13 ment measures with respect to the use of hydrofluoric acid 

14 in an alkylation unit. 

15 (b) STATIONARY SOURCE DESCRIBED.—A stationary 

16 source described in this subsection is a stationary source 

17 (as defined in section 112(r)(2)(C) of the Clean Air Act 

18 (42 U.S.C. 7412(r)(2)(C)) in North American Industry 

19 Classification System code 324— 

20 (1) for which a construction permit or operating 

21 permit has been issued pursuant to the Clean Air 

22 Act (42 U.S.C. 7401 et seq.); or 

23 (2) for which the owner or operator dem24 onstrates to the Administrator of the Environmental 

25 Protection Agency that such stationary source con26 forms or will conform to the most recent version of 


kjohnson on DSK79L0C42PROD with BILLS
3 

•HR 1155 IH

1 American Petroleum Institute Recommended Prac2 tice 751. 

Æ 


kjohnson on DSK79L0C42PROD with BILLS
I, Liang Liao, certify that:

    1.       I have reviewed this annual report on Form 10-KSB of China Finance,
Inc.;

    2.       Based on my knowledge, this annual report does not contain any
untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this
report;

    3.       Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
small business issuer as of, and for, the periods presented in this report;

    4.       The small business issuer's other certifying officers and I are
responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small
business issuer and have:

        (a)  designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the small business issuer,
including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being
prepared;

        (b)  evaluated the effectiveness of the small business issuer's
disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end
of the period covered by this report based on such evaluation; and

        (c)  disclosed in this report any change in the small business issuer's
internal control over financial reporting that occurred during the small
business issuer's fourth fiscal quarter that has materially affected, or is
reasonably likely to materially affect, the small business issuer's internal
control over financial reporting;

    5.       The small business issuer's other certifying officers and I have
disclosed, based on our most recent evaluation of internal control over
financial reporting, to the small business issuer's auditors and the audit
committee of the small business issuer's board of directors (or persons
performing the equivalent functions):

        (a)  all significant deficiencies and material weaknesses in the design
or operation of internal control over financial reporting which are reasonably
likely to adversely affect the small business issuer's ability to record,
process, summarize and report financial information; and

        (b)  any fraud, whether or not material, that involves management or
other employees who have a significant role in the small business issuer's
internal controls over financial reporting.


Dated: March 28, 2005                    /s/ Liang Liao
                                         --------------
                                         Liang Liao
                                         Chief Financial Officer,
                                         (Principal Financial Officer)
#### § 11.21 Organization.

NAD was established on October 13, 1994. Delegation of authority to the Director, NAD, appears at § 2.34 of this title. The organization is comprised of three regional offices: Eastern Regional Office, Indianapolis, Indiana; Southern Regional Office, Memphis, Tennessee; and Western Regional Office, Lakewood, Colorado; and the headquarters staff located in Alexandria, Virginia. NAD is headed by a Director. NAD is assigned responsibility for certain administrative appeals as set forth in subpart A of this part.
**Exhibit
      32.2**

















**STATEMENT
      PURSUANT TO**


**18
      U.S.C. SECTION 1350,**


**AS
      ADOPTED PURSUANT TO SECTION 906**


**OF
      THE SARBANES-OXLEY ACT OF 2002**














I,
      Harry
      M. Stokes, of InforMedix Holdings, Inc. (the “Company”), hereby certify,
      pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
      Sarbanes-Oxley Act of 2002, that:





(a)
            the
                Annual Report on Form 10-KSB of the Company for the fiscal year ended
                December 31, 2006, to which this certification accompanies (the “Annual
                Report”), fully complies with the requirements of Section 13(a) or 15(d)
                of the Securities Exchange Act of 1934;
                and





(b)
            the
                information contained in the Periodic Report fairly presents, in
                all
                material respects, the financial condition and results of operations
                of
                the Company.








Dated:
      April 27, 2007





***s/Harry
                M. Stokes***Harry
                M. Stokes,Chief
                Financial Officer




















A
      signed
      original of this written statement required by Section 906, or other document
      authenticating, acknowledging or otherwise adopting the signature that appears
      in typed form within the electronic version of this written statement required
      by Section 906, has been provided to InforMedix Holdings, Inc. and will be
      retained by InforMedix Holdings, Inc. and furnished to the Securities and
      Exchange Commission or its staff upon request.
C OURT OF A PPEALS FOR THE
F IRST D ISTRICT OF T EXAS AT H OUSTON

O RDER

Appellate case name: In the Interest of S.L.F., A.D.T., and A.A.T. , child ren

Appellate case number: 01

- 17

- 0032 9

- CV

Trial court case number: 201 5

- 43569

Trial court: 310th District Court of Harris County

Appellant is appealing the trial court’s order terminating her parental rights, signed on April 4, 2017. An appeal from a final order of termination is an accelerated appeal and the notice of appeal must be filed within 20 days fro m the date the trial court’s order is signed. See

In re K.A.F. , 160 S.W.3d 923, 924 (Tex. 2005); see also T EX

. R. A PP

. P. 26.1(b).

The notice of appeal was filed on April 26, 2017, which is not within the 20

- day time period for filing the notice of appe al in an accelerated appeal. See T EX

. R. A PP

. P. 26.1(b). However, when the notice of appeal is filed after the deadline but within 15 days after the deadline for filing the notice of appeal, a motion for extension is implied. See Verburgt v.

Dorner , 959 S.W.2d 615, 617 (Tex. 1997). Appellant’s notice of appeal was filed within this 15

- day period, but she must offer a reasonable explanation for failing to file the notice of appeal in a timely manner. See T EX

. R. A PP

. P. 10.5(b)(1)(C), 26.3; Jones v. City of Houston , 976 S.W.2d 676, 677 (Tex. 1998).

An order requesting counsel to provide a reasonable explanation for the untimely filing of the notice of appeal issued on June 22, 2017, and counsel has not responded to that order. Accordingly, unless, within 3 6 hours of the date of this notice, you respond in writing, providing a reasonable explanation for untimely filing the notice of appeal, your appeal

will be dismissed

. See T EX

. R. A PP

. P. 42.3(a), (c). You must respond in writing even if you have previous ly claimed your notice of appeal was timely filed. If counsel no longer represents appellant, counsel must immediately notify this Court.

It is so ORDERED.

Judge’s signature: /s/ Harvey Brown

 Acting individually  Acting for the Court

Date: August 7, 2017
<TABLE> <S> <C>

<ARTICLE> UT
<LEGEND>
This schedule contains summary financial information extracted from the
related Form 10-Q financial statements for The Cleveland Electric
Illuminating Company and is qualified in its entirety by reference to such
financial statements. (Amounts in 1000's.) Income tax expense includes
$7,560,000 related to other income.
</LEGEND>
<CIK> 0000020947
<NAME> THE CLEVELAND ELECTRIC ILLUMINATING COMPANY
<MULTIPLIER> 1,000
<CURRENCY> U.S.DOLLARS

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               JUN-30-1999
<EXCHANGE-RATE>                                      1
<BOOK-VALUE>                                  PER-BOOK
<TOTAL-NET-UTILITY-PLANT>                    3,018,084
<OTHER-PROPERTY-AND-INVEST>                    688,161
<TOTAL-CURRENT-ASSETS>                         426,742
<TOTAL-DEFERRED-CHARGES>                     2,134,781
<OTHER-ASSETS>                                       0
<TOTAL-ASSETS>                               6,267,768
<COMMON>                                       931,962
<CAPITAL-SURPLUS-PAID-IN>                            0
<RETAINED-EARNINGS>                             59,688
<TOTAL-COMMON-STOCKHOLDERS-EQ>                 991,650
<PREFERRED-MANDATORY>                          135,996
<PREFERRED>                                    238,325
<LONG-TERM-DEBT-NET>                         2,869,859
<SHORT-TERM-NOTES>                              55,890
<LONG-TERM-NOTES-PAYABLE>                            0
<COMMERCIAL-PAPER-OBLIGATIONS>                       0
<LONG-TERM-DEBT-CURRENT-PORT>                  144,530
<PREFERRED-STOCK-CURRENT>                       33,464
<CAPITAL-LEASE-OBLIGATIONS>                          0
<LEASES-CURRENT>                                31,867
<OTHER-ITEMS-CAPITAL-AND-LIAB>               1,766,187
<TOT-CAPITALIZATION-AND-LIAB>                6,267,768
<GROSS-OPERATING-REVENUE>                      900,794
<INCOME-TAX-EXPENSE>                            56,878
<OTHER-OPERATING-EXPENSES>                     663,322
<TOTAL-OPERATING-EXPENSES>                     712,640
<OPERATING-INCOME-LOSS>                        188,154
<OTHER-INCOME-NET>                               5,217
<INCOME-BEFORE-INTEREST-EXPEN>                 193,371
<TOTAL-INTEREST-EXPENSE>                       105,836
<NET-INCOME>                                    87,535
<PREFERRED-STOCK-DIVIDENDS>                     17,082
<EARNINGS-AVAILABLE-FOR-COMM>                   70,453
<COMMON-STOCK-DIVIDENDS>                        82,974
<TOTAL-INTEREST-ON-BONDS>                      216,278
<CASH-FLOW-OPERATIONS>                         108,208
<EPS-BASIC>                                          0
<EPS-DILUTED>                                        0


</TABLE>
#### In the Matter of the Claim of Frances Bishop, Respondent, v. Graciano Zazzara, Doing Business as Villa Restaurant, et al., Appellants. Workmen’s Compensation Board, Respondent.

Staley, Jr., J.

Appeal from a decision of the Workmen’s Compensation Board awarding death benefits. Decedent sustained a myocardial infarction on December 23, 1953, which was found to be the result of a compensable accident, and was thereafter paid compensation benefits. The ease was closed on October 14,1958 upon payment of a lump-sum nonschedule adjustment. The decedent died at the Veterans’ Administration Hos*769pital in Syracuse, New York, on July 8, 1963. The certificate of death, signed by Dr. J. A. Schaefer, recorded the cause of death as ventricular fibrillation due to recent and old myocardial infarcts and arteriosclerotic heart disease. At the hearing, Dr. Schaefer testified that the old thrombus was presumably a contributing cause to the decedent’s death. Dr. Asher Black testified that the 1953 accident was a causative factor in production of his coronary insufficiency and myoischemia thereafter present and finally resulting in his death on July 8,1963. Dr. Anthony T. Ladd testified that a coronary infarct kills heart muscle and, as a result, the heart is weaker since it has less muscle; that life expectancy after the first infarct is about 10 years; that the 1953 infarct was indirectly related to decedent’s death since it killed heart muscle, and that the 1953 infarct was a contributing factor to the death in 1963. The medical expert called by the employer denied causation, asserting the cause of death to be arteriosclerosis, a progressive disease. The board, however, was entitled to accept the evidence adduced in support of causal relation which we find to be substantial. Decision affirmed, with costs to the Workmen’s Compensation Board. Gibson, P. J., Herlihy, Reynolds, Aulisi and Staley, Jr., JJ., concur in a memorandum decision by Staley, Jr., J.